Notably, an increase in the expression of cytokine IL-6, which is involved in inflammation, has been implicated in promoting the progression of both MASLD and ALD, primarily via mitochondrial dysfunction (27, 28). Here, IL6 is linked to metabolic dysfunction-associated steatotic liver disease.